β2-adrenergic receptor agonists

Details β2-adrenergic receptor agonists β2-adrenergic receptor agonists

2007-05-15

2007-05-15

Shibuya, Mark L. (Department: 1639)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Nitrogen containing other than solely as a nitrogen in an...

C514S579000, C514S646000, C514S649000

Reexamination Certificate

active

11049447

ABSTRACT:
Disclosed are multibinding compounds which are β2 adrenergic receptor agonists and are useful in the treatment and prevention of respiratory diseases such as asthma, bronchitis. They are also useful in the treatment of nervous system injury and premature labor.

REFERENCES:
patent: 3225095 (1965-12-01), Thiele et al.
patent: 4021485 (1977-05-01), Schromm et al.
patent: 6268533 (2001-07-01), Gao et al.
patent: 6362371 (2002-03-01), Moran et al.
patent: 6541669 (2003-04-01), Moran et al.
patent: 6576793 (2003-06-01), Moran et al.
patent: 6593497 (2003-07-01), Choi et al.
patent: 6683115 (2004-01-01), Moran et al.
patent: 6747043 (2004-06-01), Moran et al.
patent: 7105701 (2006-09-01), Moran et al.
patent: 2004/0248985 (2004-12-01), Stergiades et al.
patent: 10-152460 (1998-06-01), None
Barnes, “Current Therapies for Asthma:Promise and Limitations”, CHEST, 111/2, pp. 17S-26S (1997).
Boyle, “Beta-Adrenergic Agonists”, Clinical Obstetrics and Gynecology, vol. 38, No. 4, pp. 688-696 (1995).
Greening et al., “Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid”, The Lancet, vol. 344, pp. 219-224 (1994).
1) Hoffman et al., “Catecholamines, Sympathomimetic Drugs, and Adrenergic Receptor Antagonists”, Chapter 10, pp. 199-216; and 2) Graves, “Agents That Cause Contraction or Relaxation of the Uterus”, Chapter 39, pp. 939-949, both in Goodman & Gilman's The Pharmacological Basic of Therapeutics, Ninth Edition, 1996.
Jack et al., “The 1990 Lilly Prize Lecture: A way of looking at agonism and antagonism:Lessons from salbutamol, salmeterol and other β-adrenoceptor agonists”, Br. J. clin. Pharmac., 31, pp. 501-514 (1991).
Mahler et al., “Efficacy ofSalmeterol xinafoatein the Treatment of CPOD”, CHEST, 115/4, pp. 957-965 (1999).

Affiliated with

Also associated with

Rating

β2-adrenergic receptor agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with β2-adrenergic receptor agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and β2-adrenergic receptor agonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3804608